The effects of aminoglycoside antibiotics on platelet aggregation and blood coagulation

Clinical and Applied Thrombosis/hemostasis : Official Journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis
Guoqiang ChenJie Ling

Abstract

To investigate the effects of different aminoglycoside antibiotics on platelet aggregation and blood coagulation, as well as the underlying mechanisms. Blood samples were collected and prepared as platelet-rich plasma and platelet-poor plasma samples. Then assigned into different groups for the following antibiotics treatments: gentamicin, streptomycin, etimicin, amikacin, and kanamycin, as group 0 mg/L, group 30 mg/L, group 91mg/L, and group 910 mg/L for each drugs. The maximum platelet aggregation rate induced by adenosine diphosphate, expression levels of CD62p and FIB-R, prothrombin time, activated partial thromboplastin time, thrombin time, and fibrinogen were measured. The sodium citrate and sodium heparin were used in whole blood tests for the whole blood coagulation time as well as the Ca(2+) in blood plasma. Amikacin and gentamicin could inhibit the aggregation of platelets, which contributed to the whole blood clotting disorder. Amikacin and gentamicin might inhibit the platelet aggregation by blocking the activation and release of FIB-R or probably the inhibition of endogenous clotting factor as well. This effect was not dependent on calcium ions.

References

Nov 18, 2000·Platelets·M F HoylaertsJ Vermylen
Apr 27, 2005·Seminars in Thrombosis and Hemostasis·Christian Gachet, Béatrice Hechler
Jun 16, 2005·Pharmacology & Therapeutics·Christian Gachet
Jun 16, 2005·The Annals of Pharmacotherapy·Sarah A SpinlerMaureen A Smythe
Dec 22, 2005·Frontiers in Bioscience : a Journal and Virtual Library·Swaminathan Murugappa, Satya P Kunapuli
Nov 22, 2008·Arteriosclerosis, Thrombosis, and Vascular Biology·Susan S SmythUNKNOWN 2008 Platelet Colloquium Participants
Nov 13, 2010·Arteriosclerosis, Thrombosis, and Vascular Biology·Zhenyu LiXiaoping Du
Nov 17, 2010·Clinical and Applied Thrombosis/hemostasis : Official Journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis·Anastazia A KeiEvangelos N Liberopoulos
May 20, 2011·Current Cardiology Reports·Elise CamilleriLaurent Bonello

❮ Previous
Next ❯

Citations

Sep 26, 2014·BMC Complementary and Alternative Medicine·Qian YangSiwang Wang
Dec 2, 2020·Expert Review of Anti-infective Therapy·Ruohui TangJun Fei

❮ Previous
Next ❯

Methods Mentioned

BETA
flow cytometry

Software Mentioned

SPSS12

Related Concepts

Related Feeds

Antifungals

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.

Aminoglycosides (ASM)

Aminoglycoside is a medicinal and bacteriologic category of traditional Gram-negative antibacterial medications that inhibit protein synthesis and contain as a portion of the molecule an amino-modified glycoside. Discover the latest research on aminoglycoside here.

Blood Coagulation Signaling Pathways

Coagulation is the process by which a blood clot is formed. This process includes both the formation of a platelet plug as well as a cascade of clotting factors resulting in the formation of fibrin strands. Find the latest research on coagulation signaling pathways here.

Antifungals (ASM)

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.

Aminoglycosides

Aminoglycoside is a medicinal and bacteriologic category of traditional Gram-negative antibacterial medications that inhibit protein synthesis and contain as a portion of the molecule an amino-modified glycoside. Discover the latest research on aminoglycoside here.

Blood Clotting Disorders

Thrombophilia includes conditions with increased tendency for excessive blood clotting. Blood clotting occurs when the body has insufficient amounts of specialized proteins that make blood clot and stop bleeding. Here is the latest research on blood clotting disorders.

Related Papers

Arizona Medicine
S G Axline, J N Galgiani
Nihon rinsho. Japanese journal of clinical medicine
Hiroaki Kubo, Kimikazu Shinozaki
Nihon rinsho. Japanese journal of clinical medicine
N Tanaka
Medizinische Monatsschrift für Pharmazeuten
D Eisterlehner
Nihon rinsho. Japanese journal of clinical medicine
H Kubo
© 2022 Meta ULC. All rights reserved